Axsome Therapeutics Inc

Senior Manager, Global Clinical Regulatory Leader (Remote)

United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalIndustries

Requirements

The Senior Manager, Global Clinical Regulatory Leader must have experience in providing strategic and operational direction for regulatory activities for drug products, including support for global clinical trials, regional registrations, and life cycle management. The role requires collaboration with regulatory affairs strategy teams and cross-functional teams, oversight of IND submissions in the US, and support for clinical trials applications globally. Experience in preparing and reviewing regulatory submissions such as RPDD, ODD, Annual Reports, DSURs, Scientific Advice briefing books, pre-IND, IND, Briefing Books, and MAA/BLA/NDAs is necessary. The position also requires maintaining current knowledge of relevant regulations and guidance, and liaising with CROs and internal teams for international health authority submissions.

Responsibilities

The Senior Manager, Global Clinical Regulatory Leader is responsible for providing strategic and operational direction for regulatory activities of drug products, supporting global clinical trials, regional registrations, and life cycle management. This role involves collaborating with project teams and stakeholders for local product registrations, ensuring compliance with local regulatory requirements and commercial objectives, and providing regulatory support to Global Pharmacovigilance. Key duties include preparing global regulatory strategies, maintaining knowledge of regulations, analyzing development work within global regulatory guidance, preparing CCDS, US-PI, and SmPC documents, and preparing/reviewing various regulatory submissions. Additionally, the role involves initiating and executing CTA/CTNs in the US, EU, and globally, and managing interactions with health authorities and CROs.

Skills

Regulatory Affairs
Clinical Trials
IND Submission
Global Regulatory Strategy
Life Cycle Management
Biopharmaceutical
Regulatory Compliance
SOPs

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI